StimLabs announces that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for Theracor, the first human umbilical cord-derived medical device to be offered in sheet form. This clearance marks another significant milestone for the wound care industry and reinforces StimLabs’ position at its forefront. Predicated on the clearance of Corplex P, the first FDA 510(k) cleared human umbilical cord-derived medical device for wound management provided in a particulate format, Theracor expands StimLabs’ offerings to meet the unique needs of a diverse patient population.

“After 10 years, StimLabs continues to focus on innovating technologies and driving advancements that redefine standards and progress in healthcare,” said John Daniel, Founder and Chief Executive Officer of StimLabs. “Receiving 510(k) clearance for Theracor underscores our leadership and offers greater options to clinicians and patients who benefit from human tissue-based solutions for the management of acute and chronic wounds.”